Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

139.99 +0.01 (+0.01%)
Streaming Delayed Price Updated: 10:37 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Why Is Biogen (BIIB) Stock in the Spotlight Today?
Medicare's decision not to cover the cost of the drug maker's expensive Alzheimer's drug is hitting the company's stock price today. 
Via InvestorPlace
Morning Brief: Top Stories Dominating Financial Media on Friday, April 8
Reuters Blockchain-Based Online Games Like Axie Infinity Continue To Hook Users Despite Risks Blockchain-based online games like Axie Infinity, dubbed “play-to-earn,... 
Via Benzinga
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes
Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:& 
Via Benzinga
Bear Of The Day: Biogen
Biogen’s MS revenues were $1.79 billion in the reporter quarter, including Ocrevus royalties, which declined 1% (both actual and constant currency basis) year over year. 
Via Talk Markets
3 Undervalued Stocks to Buy This Week
Here are the three undervalued stocks to buy this week. 
Via Talk Markets
Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks
Via Benzinga
Keep Eyes on Momentum in the Small-Cap Index and The Biotech Space
If BIIB can clear and close over roughly $212, it would confirm that price and momentum agree and show it's potentially ready for another move higher. 
Via Talk Markets
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week. 
Via Investor's Business Daily
Biogen Inc. (NASDAQ:BIIB) Investor Notice: Deadline in Lawsuit on April 8, 2022
San Diego, CA -- (SBWIRE) -- 03/28/2022 -- The Shareholders Foundation announced that a deadline is coming up on April 8, 2022 in the lawsuit filed for certain investors of Biogen Inc. (NASDAQ:BIIB). 
Via SBWire
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have  
Via Benzinga
Why I Sold Kohl’s Corporation Despite Possible Buyout Deal
2022 has been a headline-packed for Kohl’s and KSS stock. But after a closer look at my portfolio grader, this is why it was time to sell. 
Via InvestorPlace
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have  
Via Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
Via Benzinga
Biogen Says It Cracked The Alzheimer's Puzzle, But Investors May Need More Evidence
Patients who received Aduhelm for over two years showed declines in two markers. 
Via Investor's Business Daily
News-Filled Day
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
Via Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Hopes For A Peace Accord
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
Biogen Posts New Updates Across its Spinraza SMA Research Program
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and... 
Via Benzinga
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
These four medical stocks are outperforming the lousy market for health care investors. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri... 
Via Benzinga
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In... 
Via Benzinga
Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma
Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhelm approval. An analyst at RBC... 
Via Benzinga
Expert Ratings For Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 7... 
Via Benzinga
Biogen Has An $8 Billion Alzheimer's Opportunity — Will It Materialize?
A few key things have to go right for Biogen to snag a definitive win in Alzheimer's. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading. 
Via Benzinga
NASDAQ:BIIB Investor Alert: Lawsuit Alleges Misleading Statements by Biogen Inc.
San Diego, CA -- (SBWIRE) -- 02/23/2022 -- An investor, who purchased NASDAQ:BIIB shares, filed a lawsuit against Biogen Inc over alleged Securities Laws violations. 
Via SBWire
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept... 
Via FinancialNewsMedia
Exposures COVID-19
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.